Literature DB >> 3731150

Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.

E A Eisenhauer, W K Evans, D Raghavan, M J Desmeules, N R Murray, R Stuart-Harris, K S Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3731150

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  7 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  The Globalization of Cooperative Groups.

Authors:  Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

3.  Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

Authors:  L T Vlasveld; B G Taal; B B Kroon; M P Gallee; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.

Authors:  A Calavrezos; G Koschel; H Hüsselmann; A Taylessani; H P Heilmann; H Fabel; H J Schmoll; H Dietrich; E Hain
Journal:  Klin Wochenschr       Date:  1988-07-15

6.  An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Authors:  G Falkson; M Hunt; E C Borden; J A Hayes; C I Falkson; T J Smith
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

Review 7.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.